I agree it would, but it’s unclear to me whether they are measuring drug effect on epilepsy.
If they are, it seems to me that Angelman might be a better indication to capture that.
According to the PMS global survey, epilepsy has a prevalence of ~19% in the in the 3-12 age group being assessed in the PMS study.
In comparison, there seems to be a much higher prevalence (60-70%) of epilepsy in Angelman syndrome in the same age group (Angelman Syndrome Foundation).
I note that all four Phase 2 studies exclude participants with an unstable seizure profile.
- Forums
- ASX - By Stock
- NEU
- Phase 2
Phase 2, page-23
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.78 |
Change
-1.360(6.14%) |
Mkt cap ! $2.656B |
Open | High | Low | Value | Volume |
$22.06 | $22.11 | $20.63 | $8.616M | 407.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 593 | $20.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.78 | 10 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1065 | 20.730 |
2 | 4549 | 20.670 |
3 | 2504 | 20.660 |
1 | 300 | 20.650 |
2 | 485 | 20.640 |
Price($) | Vol. | No. |
---|---|---|
20.940 | 996 | 1 |
20.950 | 1065 | 2 |
21.000 | 1028 | 2 |
21.060 | 996 | 1 |
21.120 | 996 | 1 |
Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |